Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin Sees Symlin Playing “Foundational Role” In Obesity Program

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO-to-be Bradbury outlines plans for several obesity studies of pramlintide in combination with marketed and investigational products.

You may also be interested in...



Vivus Poised To Enter Phase III With Obesity Candidate Qnexa

Firm touts safety advantage of experimental phentermine/topiramate combination therapy.

Vivus Poised To Enter Phase III With Obesity Candidate Qnexa

Firm touts safety advantage of experimental phentermine/topiramate combination therapy.

Psylin Neurosciences Will Focus On Development of Psychiatric Drugs

New company is formed out of a joint venture between Amylin and PsychoGenics.

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel